Gokul Das, PhD, MPhil, MSRoswell Park Cancer Institute Functional analysis of mutant p53-estrogen receptor beta signaling crosstalk in high-grade serous ovarian cancer High-grade serous ovarian cancer is strikingly similar to triple negative breast cancer as both can be particularly aggressive cancers and are likely to recur. Dr. Das has found that these two diseases are […]
Read More
Denise Connolly, PhDFox Chase Cancer Center2015 Pape Family Pilot Award Sensitizing ovarian cancer to PARP inhibition PARP inhibitors are among the most promising class of targeted therapeutics for the treatment of ovarian cancer. Patients with mutations in BRCA genes and some patients with sporadic cancers are particularly sensitive to this class of drugs, presumably because […]
Read More